EPS for Assembly Biosciences, Inc. (ASMB) Expected At $-0.76; Nuveen Core Equity Alpha Fund (JCE)’s Sentiment Is 0.8

April 17, 2018 - By Vivian Park

Nuveen Core Equity Alpha Fund (JCE) investors sentiment decreased to 0.8 in 2017 Q4. It’s down -0.70, from 1.5 in 2017Q3. The ratio dived, as 12 active investment managers increased and opened new equity positions, while 15 sold and reduced their stock positions in Nuveen Core Equity Alpha Fund. The active investment managers in our database now possess: 3.16 million shares, down from 3.23 million shares in 2017Q3. Also, the number of active investment managers holding Nuveen Core Equity Alpha Fund in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 9 Increased: 8 New Position: 4.

Analysts expect Assembly Biosciences, Inc. (NASDAQ:ASMB) to report $-0.76 EPS on May, 14.They anticipate $0.05 EPS change or 6.17% from last quarter’s $-0.81 EPS. After having $-0.16 EPS previously, Assembly Biosciences, Inc.’s analysts see 375.00% EPS growth. The stock increased 6.49% or $2.92 during the last trading session, reaching $47.85. About 209,585 shares traded or 0.72% up from the average. Assembly Biosciences, Inc. (NASDAQ:ASMB) has risen 110.93% since April 17, 2017 and is uptrending. It has outperformed by 99.38% the S&P500.

Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States. The company has market cap of $977.45 million. It is involved in developing core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. It currently has negative earnings. The firm also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract.

Among 5 analysts covering Assembly Biosciences (NASDAQ:ASMB), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Assembly Biosciences had 6 analyst reports since November 8, 2017 according to SRatingsIntel. FBR Capital maintained Assembly Biosciences, Inc. (NASDAQ:ASMB) on Friday, March 9 with “Hold” rating. Chardan Capital Markets downgraded the shares of ASMB in report on Friday, April 13 to “Neutral” rating.

The stock increased 1.21% or $0.18 during the last trading session, reaching $15.07. About 34,933 shares traded. Nuveen Core Equity Alpha Fund (JCE) has risen 14.88% since April 17, 2017 and is uptrending. It has outperformed by 3.33% the S&P500.

Shaker Financial Services Llc holds 1.09% of its portfolio in Nuveen Core Equity Alpha Fund for 158,411 shares. Advisors Asset Management Inc. owns 1.07 million shares or 0.26% of their US portfolio. Moreover, Karpus Management Inc. has 0.22% invested in the company for 327,079 shares. The California-based Clenar Muke Llc has invested 0.02% in the stock. Cetera Advisors Llc, a Colorado-based fund reported 25,679 shares.

Assembly Biosciences, Inc. (NASDAQ:ASMB) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>